Establishment Labs Announces 3-Year Mia Femtech Clinical Results At 9th World Symposium On Ergonomic Implants; There Were Also No Reports Of Infection, Hematoma, Or Seroma Requiring Intervention In The Study And No Reports Of Changes In Nipple Or Breast Sensation; The Follow-Up Compliance Rate At 3-Years Was 93%
Portfolio Pulse from Benzinga Newsdesk
Establishment Labs Holdings Inc. (NASDAQ:ESTA) announced positive three-year clinical results for its Mia Femtech™ product at the 9th World Symposium on Ergonomic Implants. The study showed no major complications, such as capsular contracture or ruptures, and a high follow-up compliance rate of 93%.
October 31, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Establishment Labs Holdings Inc. reported favorable three-year clinical results for its Mia Femtech™ product, with no major complications and a high compliance rate, potentially boosting investor confidence.
The positive clinical results with no major complications and a high compliance rate are likely to enhance investor confidence in Establishment Labs' product, potentially leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100